FDA grants Fast Track to Imugene blood cancer therapy

Imugene (ASX:IMU) announced that the US Food and Drug Administration has granted Fast Track Designation to its novel therapy, azer-cel.

The designation specifically targets two blood cancer indications with critical unmet medical needs: relapsed or refractory chronic lymphocytic leukaemia / small lymphocytic lymphoma and relapsed or refractory marginal zone lymphoma.

The FDA’s Fast Track programme is structured to accelerate the development and expedite the review of therapeutics designed for serious or life-threatening conditions.

By securing this status, Imugene gains substantial advantages, including more frequent engagement and meetings with the FDA to discuss comprehensive development plans.

Furthermore, Azer-Cel may now benefit from a rolling review of its regulatory submissions, alongside potential eligibility for accelerated approval and priority review, provided it satisfies the necessary clinical criteria.

The study demonstrated a remarkable 100% objective response rate within the CAR T-naive CLL/SLL cohort, alongside an 83% ORR in the MZL cohort, which notably included four complete responses.

Unlike traditional autologous CAR T-cell therapies that suffer from severe logistical constraints—often requiring a complex, three-to-six-week manufacturing window using a patient's own cells—azer-cel represents a major paradigm shift.